$RVNC
Revance Therapeutics, Inc. Stock $rvnc

$rvnc Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-Q Financial Statement

#000147929017000042 Filed on November 03, 2017

Income Statement

Concept	2017 Q4	2017 Q3	2016 Q3
Revenue	$37.00K	$75.00K	$75.00K
YoY Change	-50.67%	0.0%	0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$11.89M	$9.148M	$7.502M
YoY Change	67.46%	21.94%	28.75%
% of Gross Profit
Research & Development	$21.00M	$21.64M	$10.30M
YoY Change	67.6%	110.21%	-20.9%
% of Gross Profit
Depreciation & Amortization	$370.0K	$380.0K	$370.0K
YoY Change	-2.63%	2.7%	-27.45%
% of Gross Profit
Operating Expenses	$32.89M	$30.79M	$17.80M
YoY Change	67.55%	73.0%	-5.55%
Operating Profit		-$30.72M	-$17.72M
YoY Change		73.31%	-5.57%
Interest Expense	$10.00K	$104.0K	$256.0K
YoY Change	-200.0%	-59.38%	-34.36%
% of Operating Profit
Other Income/Expense, Net	-$140.0K	-$128.0K	-$138.0K
YoY Change	7.69%	-7.25%	40.82%
Pretax Income	-$35.91M	-$30.65M	-$17.98M
YoY Change	33.99%	70.47%	-6.26%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$40.62M	-$30.65M	-$17.98M
YoY Change	51.54%	70.49%	-6.24%
Net Earnings / Revenue	-109772.97%	-40868.0%	-23970.67%
Basic Earnings Per Share			-$0.64
Diluted Earnings Per Share	-$1.139M	-$1.013M	-$0.64
COMMON SHARES
Basic Shares Outstanding	30.93M shares	30.82M shares	28.16M shares
Diluted Shares Outstanding			28.16M shares

Balance Sheet

Concept	2017 Q4	2017 Q3	2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$282.9M	$153.4M	$201.3M
YoY Change	52.51%	-23.8%	41.86%
Cash & Equivalents	$282.9M	$56.32M	$130.5M
Short-Term Investments	$0.00	$97.10M	$70.80M
Other Short-Term Assets	$444.0K	$2.800M	$7.400M
YoY Change	172.39%	-62.16%	362.5%
Inventory
Prepaid Expenses	$1.823M
Receivables	$48.00K
Other Receivables
Total Short-Term Assets	$285.2M	$156.3M	$208.7M
YoY Change	48.01%	-25.12%	45.42%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.250M	$11.50M	$17.39M
YoY Change	-12.61%	-33.85%	-9.71%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments			$0.00
YoY Change			-100.0%
Other Assets	$658.0K	$836.0K	$213.0K
YoY Change	31.6%	292.49%	3450.0%
Total Long-Term Assets	$10.49M	$12.92M	$18.18M
YoY Change	-10.09%	-28.95%	-17.44%
TOTAL ASSETS
Total Short-Term Assets	$285.2M	$156.3M	$208.7M
Total Long-Term Assets	$10.49M	$12.92M	$18.18M
Total Assets	$295.7M	$169.2M	$226.9M
YoY Change	44.7%	-25.42%	37.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.805M	$6.680M	$2.871M
YoY Change	81.27%	132.67%	5.13%
Accrued Expenses	$12.23M	$12.07M	$11.31M
YoY Change	-1.55%	6.75%	88.75%
Deferred Revenue	$0.00
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.900M	$2.700M	$3.300M
YoY Change	-45.71%	-18.18%	10.0%
Total Short-Term Liabilities	$20.90M	$21.48M	$17.52M
YoY Change	6.39%	22.61%	49.21%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$2.800M
YoY Change	-100.0%	-100.0%	-54.84%
Other Long-Term Liabilities	$0.00	$0.00	$100.0K
YoY Change	-100.0%	-100.0%	-98.08%
Total Long-Term Liabilities	$0.00	$0.00	$100.0K
YoY Change	-100.0%	-100.0%	-99.12%
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.90M	$21.48M	$17.52M
Total Long-Term Liabilities	$0.00	$0.00	$100.0K
Total Liabilities	$26.85M	$27.13M	$26.14M
YoY Change	-1.59%	3.77%	12.89%
SHAREHOLDERS EQUITY
Retained Earnings	-$542.2M	-$506.3M	-$394.7M
YoY Change	28.61%	28.25%	27.26%
Common Stock	$811.0M	$648.4M	$595.4M
YoY Change	35.47%	8.89%	31.58%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$268.8M	$142.1M	$200.7M
YoY Change
Total Liabilities & Shareholders Equity	$295.7M	$169.2M	$226.9M
YoY Change	44.7%	-25.42%	37.06%

Cashflow Statement

Concept	2017 Q4	2017 Q3	2016 Q3
OPERATING ACTIVITIES
Net Income	-$40.62M	-$30.65M	-$17.98M
YoY Change	51.54%	70.49%	-6.24%
Depreciation, Depletion And Amortization	$370.0K	$380.0K	$370.0K
YoY Change	-2.63%	2.7%	-27.45%
Cash From Operating Activities	-$28.39M	-$21.47M	-$14.35M
YoY Change	110.76%	49.62%	4.67%
INVESTING ACTIVITIES
Capital Expenditures	-$490.0K	-$530.0K	-$160.0K
YoY Change	-5.77%	231.25%	-71.43%
Acquisitions
YoY Change
Other Investing Activities	$96.79M	$15.00M	$93.01M
YoY Change	-284.96%	-83.87%	-9308.91%
Cash From Investing Activities	$96.30M	$14.47M	$92.84M
YoY Change	-282.25%	-84.41%	-6013.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	158.7M	9.120M	-660.0K
YoY Change	-23780.6%	-1481.82%	-107.06%
NET CHANGE
Cash From Operating Activities	-28.39M	-21.47M	-14.35M
Cash From Investing Activities	96.30M	14.47M	92.84M
Cash From Financing Activities	158.7M	9.120M	-660.0K
Net Change In Cash	226.6M	2.120M	77.83M
YoY Change	-438.27%	-97.28%	-1412.48%
FREE CASH FLOW
Cash From Operating Activities	-$28.39M	-$21.47M	-$14.35M
Capital Expenditures	-$490.0K	-$530.0K	-$160.0K
Free Cash Flow	-$27.90M	-$20.94M	-$14.19M
YoY Change	115.44%	47.57%	7.91%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	rvnc	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-70989000	USD
	rvnc	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-7178000	USD
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	rvnc	Cashand Cash Equivalentsand Investments Operating Plan Funding Term Minimum CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum	P12M
	dei	Document Period End Date DocumentPeriodEndDate	2017-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001479290
CY2017Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	30934688	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	1999-08-10
	dei	Entity Information Date To Change Former Legal Or Registered Name EntityInformationDateToChangeFormerLegalOrRegisteredName	2005-04-19
	dei	Entity Registrant Name EntityRegistrantName	Revance Therapeutics, Inc.
CY2015Q4	rvnc	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	202050000	USD
CY2016Q3	rvnc	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	131061000	USD
CY2016Q4	rvnc	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	64082000	USD
CY2017Q3	rvnc	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	56904000	USD
CY2016Q4	rvnc	Financing Lease Obligation Noncurrent Netof Current Portion FinancingLeaseObligationNoncurrentNetofCurrentPortion	1872000	USD
CY2017Q3	rvnc	Financing Lease Obligation Noncurrent Netof Current Portion FinancingLeaseObligationNoncurrentNetofCurrentPortion	0	USD
CY2016Q4	rvnc	Financing Obligation Current FinancingObligationCurrent	3475000	USD
CY2017Q3	rvnc	Financing Obligation Current FinancingObligationCurrent	2727000	USD
CY2017Q3	rvnc	Financing Obligation Future Minimum Payments Due FinancingObligationFutureMinimumPaymentsDue	1897000	USD
CY2017Q3	rvnc	Financing Obligation Future Minimum Payments Duein Two Years FinancingObligationFutureMinimumPaymentsDueinTwoYears	949000	USD
CY2017Q3	rvnc	Financing Obligation Future Minimum Payments Remainderof Fiscal Year FinancingObligationFutureMinimumPaymentsRemainderofFiscalYear	948000	USD
CY2016Q3	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	-167000	USD
	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	-595000	USD
CY2017Q3	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	-44000	USD
	rvnc	Gain Losson Derivative Instruments Contract Net Pretax GainLossonDerivativeInstrumentsContractNetPretax	-211000	USD
CY2016Q3	rvnc	Interest Expense Capitalized InterestExpenseCapitalized	0	USD
	rvnc	Interest Expense Capitalized InterestExpenseCapitalized	0	USD
CY2017Q3	rvnc	Interest Expense Capitalized InterestExpenseCapitalized	21000	USD
	rvnc	Interest Expense Capitalized InterestExpenseCapitalized	37000	USD
CY2016Q3	rvnc	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-17978000	USD
	rvnc	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-62468000	USD
CY2017Q3	rvnc	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-30651000	USD
	rvnc	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-84680000	USD
CY2016Q3	rvnc	Noncash Interest Expense NoncashInterestExpense	98000	USD
	rvnc	Noncash Interest Expense NoncashInterestExpense	315000	USD
CY2017Q3	rvnc	Noncash Interest Expense NoncashInterestExpense	41000	USD
	rvnc	Noncash Interest Expense NoncashInterestExpense	180000	USD
CY2017Q3	rvnc	Working Capital Surplus WorkingCapitalSurplus	134800000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3754000	USD
CY2017Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	6680000	USD
CY2017Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	648329000	USD
CY2016Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2755000	USD
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3146000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8984000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1029000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-382000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12418000	USD
CY2017Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12069000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-45000	USD
CY2017Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-43000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	598630000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9820000	USD
CY2016Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1949000	USD
CY2017Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2016Q4	us-gaap	Assets Assets	204360000	USD
CY2017Q3	us-gaap	Assets Assets	169183000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	192695000	USD
CY2017Q3	us-gaap	Assets Current AssetsCurrent	156267000	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	182665000	USD
CY2017Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	152597000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5000	USD
CY2017Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	50000	USD
CY2017Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	43000	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	182710000	USD
CY2017Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	152640000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63502000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	56323000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	185500000	USD
CY2017Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	153400000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	95000000	shares
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	95000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28648954	shares
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30935094	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28648954	shares
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30935094	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	29000	USD
CY2017Q3	us-gaap	Common Stock Value CommonStockValue	31000	USD
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	11000	USD
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	3648000	USD
	us-gaap	Depreciation Depreciation	1096000	USD
CY2017Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	3418000	USD
	us-gaap	Depreciation Depreciation	1068000	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18110000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-62412000	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-30579000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-84677000	USD
CY2016Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2022000	USD
CY2017Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2233000	USD
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.64
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.22
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.01
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.86
CY2016Q2	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	100000	USD
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	200000	USD
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	0	USD
CY2016Q3	us-gaap	Financing Interest Expense FinancingInterestExpense	98000	USD
	us-gaap	Financing Interest Expense FinancingInterestExpense	315000	USD
CY2017Q3	us-gaap	Financing Interest Expense FinancingInterestExpense	62000	USD
	us-gaap	Financing Interest Expense FinancingInterestExpense	217000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	200000	USD
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	2749000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	5821000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-848000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	488000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5852000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-4632000	USD
CY2016Q3	us-gaap	Interest Expense InterestExpense	256000	USD
	us-gaap	Interest Expense InterestExpense	857000	USD
CY2017Q3	us-gaap	Interest Expense InterestExpense	104000	USD
	us-gaap	Interest Expense InterestExpense	439000	USD
CY2016Q3	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	158000	USD
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	542000	USD
CY2017Q3	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	63000	USD
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	259000	USD
	us-gaap	Interest Paid InterestPaid	542000	USD
	us-gaap	Interest Paid InterestPaid	259000	USD
CY2016Q3	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	306000	USD
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	940000	USD
CY2017Q3	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	341000	USD
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	999000	USD
CY2014Q1	us-gaap	Lessee Leasing Arrangements Operating Leases Renewal Term LesseeLeasingArrangementsOperatingLeasesRenewalTerm	P36M
CY2016Q4	us-gaap	Liabilities Liabilities	27289000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	430000	USD
CY2017Q3	us-gaap	Liabilities Liabilities	27127000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	204360000	USD
CY2017Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	169183000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19647000	USD
CY2017Q3	us-gaap	Liabilities Current LiabilitiesCurrent	21476000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1974000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	37278000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-22656000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	22490000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-46359000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-66900000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-66946000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-17978000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-62468000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-30651000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-84680000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	29000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	429000	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	17798000	USD
	us-gaap	Operating Expenses OperatingExpenses	61775000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	30791000	USD
	us-gaap	Operating Expenses OperatingExpenses	84868000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-17723000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-61550000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-30716000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-84643000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	39282000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	5947000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	5763000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	5578000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	20644000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	1350000	USD
CY2016Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1300000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	2600000	USD
CY2017Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1300000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	4000000	USD
	us-gaap	Operations Commenced Date1 OperationsCommencedDate1	2002-06-30
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	500000	USD
CY2017Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	836000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-132000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	56000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	72000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	3000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	100000	USD
CY2017Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-138000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-406000	USD
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-128000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-386000	USD
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	243000	USD
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	441000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	359000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2037000	USD
CY2016Q2	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	1800000	USD
CY2017Q2	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	100000	USD
	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	1800000	USD
	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	100000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	159754000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	36028000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1152000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	1.000
CY2017Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000000	shares
CY2017Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7167000	USD
CY2017Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2827000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	38760000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	139050000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	60655000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	1000000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1250000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2116000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10585000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11500000	USD
CY2017Q3	us-gaap	Purchase Obligation PurchaseObligation	1200000	USD
	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	2622000	USD
	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	2727000	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2000000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10296000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	37851000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21643000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	59357000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	2000000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	580000	USD
CY2017Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	580000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-421543000	USD
CY2017Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-506261000	USD
CY2016Q3	us-gaap	Revenues Revenues	75000	USD
	us-gaap	Revenues Revenues	225000	USD
CY2017Q3	us-gaap	Revenues Revenues	75000	USD
	us-gaap	Revenues Revenues	225000	USD
CY2017Q3	us-gaap	Stockholders Equity StockholdersEquity	142056000	USD
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	28160458	shares
CY2016Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7502000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	21975000	USD
CY2017Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9148000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	25511000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	8984000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	9820000	USD
CY2016Q4	us-gaap	Short Term Investments ShortTermInvestments	122026000	USD
CY2017Q3	us-gaap	Short Term Investments ShortTermInvestments	97117000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	177071000	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	28085541	shares
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	30270260	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	29623805	shares
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Medicis Settlement</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2009, the Company entered into a license agreement with Medicis Pharmaceutical Corporation, or Medicis, granting Medicis worldwide aesthetic and dermatological rights to the Company’s investigational botulinum toxin type A product candidates. In October 2012, the Company entered into a settlement and termination agreement with Medicis. The terms of the settlement provided for the reacquisition of the rights related to all territories of RT002 injectable and RT001 topical from Medicis and for consideration payable by the Company to Medicis of up to </font><font style="font-family:inherit;font-size:10pt;">$25.0 million</font><font style="font-family:inherit;font-size:10pt;">, comprised of (i) an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$7.0 million</font><font style="font-family:inherit;font-size:10pt;">, which was paid in 2012, (ii) a proceeds sharing arrangement payment of </font><font style="font-family:inherit;font-size:10pt;">$14.0 million</font><font style="font-family:inherit;font-size:10pt;"> due upon specified capital raising achievements by the Company, of which </font><font style="font-family:inherit;font-size:10pt;">$6.9 million</font><font style="font-family:inherit;font-size:10pt;"> was paid in 2013 and </font><font style="font-family:inherit;font-size:10pt;">$7.1 million</font><font style="font-family:inherit;font-size:10pt;"> in 2014, and (iii) a Product Approval Payment of </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> to be paid upon the achievement of regulatory approval for RT002 injectable or RT001 topical by the Company. Medicis was subsequently acquired by Valeant Pharmaceuticals International, Inc. in December 2012.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that the settlement provisions related to the proceeds sharing arrangement payment in (ii) above and Product Approval Payment in (iii) above were derivative instruments that require fair value accounting as a liability and periodic fair value remeasurements until settled. </font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company determined the fair value of its liability for the Product Approval Payment was </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;">, which was measured by assuming a term of </font><font style="font-family:inherit;font-size:10pt;">2.75</font><font style="font-family:inherit;font-size:10pt;"> years, a risk-free rate of </font><font style="font-family:inherit;font-size:10pt;">1.58%</font><font style="font-family:inherit;font-size:10pt;"> and a credit risk adjustment of </font><font style="font-family:inherit;font-size:10pt;">7.00%</font><font style="font-family:inherit;font-size:10pt;">. The Company’s assumption for the expected term is based on an expected Biologics License Application, or BLA, approval in 2020. The Company did not make any payments under the Product Approval Payment during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of Condensed Consolidated Financial Statements in conformity with US GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and accompanying notes. Such management estimates include accruals, stock-based compensation, the fair value of a derivative liability, impairment of long-lived assets, and the valuation of deferred tax assets. The Company bases its estimates on historical experience and on assumptions that it believes are reasonable, however, actual results could significantly differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001479290-17-000042-index-headers.html	Edgar Link	pending
0001479290-17-000042-index.html	Edgar Link	pending
0001479290-17-000042.txt	Edgar Link	pending
0001479290-17-000042-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rvnc-20170930.xml	Edgar Link	completed
rvnc-20170930.xsd	Edgar Link	pending
rvnc-20170930_cal.xml	Edgar Link	unprocessable
rvnc-20170930_def.xml	Edgar Link	unprocessable
rvnc-20170930_lab.xml	Edgar Link	unprocessable
rvnc-20170930_pre.xml	Edgar Link	unprocessable
rvnc-q317exhibit101.htm	Edgar Link	pending
rvnc-q317exhibit311.htm	Edgar Link	pending
rvnc-q317exhibit312.htm	Edgar Link	pending
rvnc-q317exhibit321.htm	Edgar Link	pending
rvnc-q317exhibit322.htm	Edgar Link	pending
rvncq31710q.htm	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RVNC
Revance Therapeutics, Inc. Stock $rvnc

2017 Q4 Form 10-Q Financial Statement

#000147929017000042 Filed on November 03, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RVNC Revance Therapeutics, Inc. Stock $rvnc

2017 Q4 Form 10-Q Financial Statement

#000147929017000042 Filed on November 03, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RVNC
Revance Therapeutics, Inc. Stock $rvnc